PhRMA Statement on HELP ACT

WASHINGTON, D.C. (January 17, 2018) – Today, Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Stephen J. Ubl provided the following statement:

“PhRMA welcomes the introduction of legislation by Senator Bill Cassidy to review and fix the 340B program. As stated in the recently released House Energy and Commerce Committee report, there are a number of flaws with the 340B program that must be addressed, including more oversight to ensure the program is meeting its intent of helping vulnerable and uninsured patients. If passed, this legislation will enable Congress and the Health Resources and Services Administration to take additional, much-needed action to get the 340B program back on track.

“We saw increased attention on the 340B program throughout 2017 from the Hill and the Administration, and it is encouraging to see continued focus in 2018. There has long been bipartisan support for fixing 340B, including recently introduced bipartisan legislation in the House, and PhRMA looks forward to working with all stakeholders to keep this momentum going.”

About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $65.5 billion in 2016 alone.

Connect with PhRMA
For information on how innovative medicines save lives, please visit:


This website uses cookies and other tracking technologies to optimize performance, preferences, usage, and statistics. By clicking “Accept All”, you consent to store on your device the cookies and other tracking technologies that require consent. You can tailor or change your preferences by clicking “Manage My Cookies”. You can check our privacy policy for more information.